Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3593-3598

  Wang, Jiarui ^a   Wang, Huiling ^a   Zhao, Long ^a   Fan, Sufang ^b   Yang, Zhonghai ^a   Gao, Fei ^a   Chen, Lixia ^a   Xiao, Gary Guishan ^c   Molnár, Joseph ^d   Wang, Qi ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Second Hospital of Shijiazhuang   (China)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Down regulation; Drug resistance; Lung cancer; P glycoprotein

Indexed keywords

CISPLATIN; ETOPOSIDE; GLYCOPROTEIN P; MESSENGER RNA; VERAPAMIL; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; LUNG TUMOR; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUNG NEOPLASMS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77958577303     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cohen V and Khuri FR: Chemoprevention of lung cancer: current status and future prospects. Cancer Metastasis Rev 21: 349-362, 2002. (Pubitemid 36071920)
2. Ihde DC and Minna JD: Non-small cell lung cancer. Part II: Treatment. Curr Probl Cancer 15: 105-154, 1991.
3. Nishio K, Nakamura T, Koh Y, Suzuki T, Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin Oncol 11: 109-115, 1999.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
5. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
6. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485, 2003.
7. Fuqua SA, Moretti-Rojas IM, Schneider SL and McGuire WL: P-glycoprotein expression in human breast cancer cells. Cancer Res 47: 2103-2106, 1987.
8. Sugimoto Y and Tsuruo T: DNA-mediated transfer and cloning of a human multidrug-resistant gene of adriamycin-resistant myelogenous leukemia K562. Cancer Res 47: 2620-2625, 1987.
9. Hamada H and Tsuruo T: Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
10. Doyle LA: Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20: 326-337, 1993. (Pubitemid 23241681)
11. Tsuruo T: Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 42: 237-243, 2003.
12. + antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci 16: 159-165, 2002.
13. Muller C, Goubin F, Ferrandis E, Cornil-Scharwtz I, Bailly JD, Bordier C, Benard J, Sikic BI and Laurent G: Evidence for transcriptional control of human MDR1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol Pharmacol 47: 51-56, 1995.
14. Sulova Z, Macejova D, Seres M, Sedlak J, Brtko J and Breier A: Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol In Vitro 22: 96-105, 2008.
15. Wang Q, Wang T, Wang Y, Wang W, Wang Y, Hu X, Shao S, Zhang J and Suo Z: VP-16 resistance in the NCI-H460 human lung cancer cell line is significantly associated with glucose-regulated protein78 (GRP78) induction. Anticancer Res 27: 2359-2364, 2007.
16. Kim JR, Oh DR, Cha MH, Pyo BS, Rhee JH, Choy HE, Oh WK and Kim YR: Protective effect of polygoni cuspidati radix and emodin on Vibrio vulnificus cytotoxicity and infection. J Microbiol 46: 737-743, 2008.
17. Chen LM, Liang YJ, Zhang X, Su XD, Dai CL, Wang FP, Yan YY, Tao LY and Fu LW: Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res 29: 4597-4604, 2009.
18. Pastan I and Gottesman M: Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393, 1987.
19. Bansal T, Jaggi M, Khar RK and Talegaonkar S: Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12: 46-78, 2009.
20. Hosey MM and Lazdunski M: Calcium channels: molecular pharmacology, structure and regulation. J Membr Biol 104: 81-105, 1988.
21. Breier A, Barancik M, Sulova Z and Uhrik B: P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5: 457-468, 2005.
22. Triller N, Korosec P, Kern I, Kosnik M and Debeljak A: Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54: 235-240, 2006.
23. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE and Cabot MC: Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3: 633-639, 2004.
24. Lagas JS, Fan L, Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH and Schinkel AH: P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 16: 130-140, 2010.
25. Murphy L, Henry M, Meleady P, Clynes M and Keenan J: Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochim Biophys Acta 1784: 1184-1191, 2008.
26. Johnstone RW, Cretney E and Smyth MJ: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93: 1075-1085, 1999.